1
/
of
1
Custom Adenine Base Editor (Plasmid)
Custom Adenine Base Editor (Plasmid)
SKU:
Regular price
$595
Regular price
Sale price
$595
Unit price
/
per
Selected promoter is too long for this design
Couldn't load pickup availability
Precision A-to-G base editing in plasmid format for transient expression or screening. Choose from single-vector designs featuring compact ABE8e variants (SpCas9, SaCas9, CjCas9, Nme2Cas9, SauriCas9) with complementary PAM specificities. Ideal for target validation, dose-response optimization, cell engineering workflows, or any application requiring flexible, non-viral delivery.
U6-(gRNA)-(pro)-ABE7.10-bGHpAExpress gRNA under U6 and ABE7.10 under selected pro for original adenine base editing with broad literature validation
- ABE7.10 Base Editor: First adenine base editor validated in human cells, achieving ~50% A-to-G conversion at positions 4–7 with ≤0.1% indels. Addresses the class of pathogenic mutations responsible for ~48% of disease-causing SNPs. Foundational reference for all subsequent ABE development, using an evolved TadA*–SpCas9 D10A nickase heterodimer.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-ABE8e-bGHpAExpresses sgRNA under U6 and ABE8e under selected promoter for single-AAV adenine base editing with NNGRRT PAM
- ABE8e Base Editor: Enhanced ABE with 590-fold faster deamination than ABE7.10. PACE evolution enables 1.5-3× improved efficiency with broader editing window.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaABE8e-bGHpAExpress sgRNA under U6 and SaABE8e under selected promoter for single-AAV adenine base editing with NNGRRT PAM
- SaABE8e Base Editor: Compact adenine base editor using S. aureus Cas9 (NNGRRT PAM). TadA8e deaminase provides 590-fold faster deamination than ABE7.10 with editing window at positions 4-9.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaABE8e-V106W-bGHpAExpress sgRNA under U6 and SaABE8e V106W under selected promoter for minimized off-target RNA editing
- SaABE8e-V106W Base Editor: SaABE8e variant with V106W mutation in TadA* domain, reducing off-target RNA editing while maintaining DNA editing efficiency.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaKKH-ABE8e-bGHpAExpress sgRNA under U6 and SaKKH-ABE8e under selected promoter for expanded NNNRRT PAM targeting scope
- SaKKH-ABE8e Base Editor: Expanded-PAM variant of SaABE8e with KKH mutations (E782K/N968K/R1015H) enabling NNNRRT PAM recognition.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-CjABE8e-bGHpAExpresses sgRNA under U6 and CjABE8e under selected promoter for ultra-compact single-AAV delivery
- CjABE8e Base Editor: Ultra-compact adenine base editor using Campylobacter jejuni Cas9. Smallest ABE architecture (~3.8 kb) with 22-nt protospacer and editing window at positions 3-11.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-Nme2ABE8e-bGHpAExpress sgRNA under U6 and Nme2ABE8e under selected promoter for A/T-rich region targeting with N4CC PAM
- Nme2ABE8e Base Editor: Ultra-compact adenine base editor using Nme2Cas9 with N4CC PAM, enabling targeting of A-rich sequences.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SauriABE8e-bGHpAExpress sgRNA under U6 and SauriABE8e under selected promoter for alternative PAM specificity and genome coverage
- SauriABE8e Base Editor: Compact adenine base editor using S. auricularis Cas9, providing alternative PAM specificity for expanded targeting.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
Deliverables
- Titer: 1 µg/mL or higher
- Delivery Timeline: 12–14 days
Specifications
High copy plasmid DNA produced in E. coli using the proprietary Ambryon backbone with pMB1 origin of replication and ampicillin resistance. Bacteria are cultured in LB medium at 37°C and harvested at late exponential phase. Cells are lysed by alkaline lysis and purified by endotoxin-free anion-exchange chromatography. Final DNA is resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and quality-verified by A260/A280 spectrophotometry (≥1.8) and sequence confirmation. Store at -20°C and avoid repeated freeze-thaw cycles. Ships at ambient temperature.
References
Share
